News headlines about Novavax (NASDAQ:NVAX) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novavax earned a daily sentiment score of 0.07 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.0431726601367 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s scoring:
Several research firms recently weighed in on NVAX. S&P Equity Research dropped their price target on Novavax from $1.81 to $1.35 in a research report on Wednesday, January 10th. B. Riley set a $10.00 target price on Novavax and gave the stock a “buy” rating in a research report on Thursday, January 11th. Ladenburg Thalmann Financial Services increased their price objective on Novavax to $2.50 and gave the company a “buy” rating in a report on Thursday, January 11th. BidaskClub raised Novavax from a “hold” rating to a “buy” rating in a report on Saturday, December 30th. Finally, Citigroup upgraded Novavax from a “neutral” rating to a “buy” rating and set a $2.00 target price for the company in a research note on Tuesday, October 31st. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $2.64.
Novavax (NASDAQ:NVAX) traded up $0.04 during midday trading on Wednesday, hitting $2.03. The stock had a trading volume of 3,657,611 shares, compared to its average volume of 13,520,000. The firm has a market cap of $636.64, a PE ratio of -2.99 and a beta of 2.68. Novavax has a one year low of $0.73 and a one year high of $2.32. The company has a debt-to-equity ratio of -4.28, a current ratio of 3.31 and a quick ratio of 3.31.
COPYRIGHT VIOLATION NOTICE: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/14/novavax-nvax-earning-somewhat-positive-media-coverage-study-finds.html.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.